BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Feb 22, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Feb. 20 that will take its lead candidate, acne therapy BX001, into the clinic within the next few months....
BC Extra | Feb 20, 2019
Financial News

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday that will take its lead candidate, acne therapy BX001, into the clinic within the next few months. The...
BC Week In Review | Oct 5, 2018
Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

BioSense Global LLC (East Rutherford, N.J.) exercised its option under a 2017 deal to acquire exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs will receive an...
BC Week In Review | Jul 7, 2017
Clinical News

Cara's oral analgesic misses in Phase IIb

Cara Therapeutics Inc. (NASDAQ:CARA) reported top-line data from the Phase IIb CLIN2002 trial in 476 patients with osteoarthritis (OA) of the hip or knee who were experiencing moderate to severe pain showing that twice-daily 1,...
BC Week In Review | Apr 7, 2017
Clinical News

IV CR845: Ph II/III CLIN2101 data

Top-line data from 174 dialysis-dependent chronic kidney disease (CKD) patients with moderate to severe uremic pruritus in the Phase II portion of the double-blind, U.S. Phase II/III CLIN2101 trial showed that IV CR845 met the...
BC Innovations | Jan 3, 2017
Distillery Therapeutics

Neurology; dermatology

INDICATION: Pain; itch Mouse and rat studies suggest a G protein-biased KOR agonist could help treat pain and itch without the sedation and dysphoria caused by unbiased KOR agonists. A previously reported triazole-based, biased KOR...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Apr 11, 2016
Clinical News

Subcutaneous beloranib: Additional Phase III data

Additional data from the double-blind, U.S. Phase III bestPWS (ZAF-311) trial in 107 patients with Prader-Willi syndrome showed that twice-weekly 1.8 and 2.4 mg doses of subcutaneous beloranib each met the secondary endpoints of reducing...
Items per page:
1 - 10 of 53